{"id":"W4399480368","doi":"10.1200/jco.24.01001","title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Ono Pharmaceutical; Chugai Pharmaceutical; Seagen; MacroGenics; Astex Pharmaceuticals; Novocure; Regeneron Pharmaceuticals; Yuhan; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; G1 Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001268969,0.0002235169,0.001165213,0.0001900202,0.00005209901,0.00002630334,0.0001841198,0.0002492488,0.00007083625],"category_scores_gemma":[0.0007074937,0.0001237674,0.0001693502,0.0003267381,0.0001271613,0.0001565678,0.00003667355,0.001258936,0.000005720636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001286122,"about_ca_system_score_gemma":0.00356332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00155365,"about_ca_topic_score_gemma":0.002459119,"domain_scores_codex":[0.9959704,0.0006323373,0.002337443,0.0003731467,0.0003805854,0.000306108],"domain_scores_gemma":[0.9921026,0.006255532,0.0009880915,0.0002076093,0.000235349,0.0002108311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.249427,0.03614108,0.2411817,0.0001646232,0.003567251,0.03635366,0.02214143,0.000120043,0.001613751,0.00002198229,0.00402938,0.4052382],"study_design_scores_gemma":[0.2643289,0.07871974,0.6419293,0.001331285,0.002353752,0.0002036815,0.002860317,0.0005690453,0.0001779549,0.00006956042,0.007092542,0.0003639851],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886831,0.001288598,0.00005269154,0.005898394,0.00195128,0.001002324,0.0001196607,0.00002113366,0.0009828201],"genre_scores_gemma":[0.9968156,0.001487473,0.0002890978,0.0005310103,0.0005971023,0.00002860523,0.00005366707,0.00003419923,0.0001632809],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4048742,"threshold_uncertainty_score":0.6321177,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04980772707266565,"score_gpt":0.4339217826342359,"score_spread":0.3841140555615702,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}